Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Feb 27;10(2):e0118153. doi: 10.1371/journal.pone.0118153

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Mukherjee et al

This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.

PMC Copyright notice

Fig 5 — A) Immunoblots with anti-HS1 and anti-Vav1 showing depletion of HS1 and Vav1 after 72 hrs of siRNA treatment. B) Decrease in TEM in transwell assay by NK cells treated with Vav1 siRNA, compared to control siRNA. Number of cells in the lower chamber, as a percentage of the mean of the control sample value on each day, with box and whisker plots. Boxes: 25th to 75th percentiles; whiskers: minimum and maximum values. N = 6. Asterisks indicate **P<0.005 (unpaired Student’s t-test). C) Left panel: Immunoblot with anti-HS1. The left lane shows the absence of HS1 in an anti-HS1 immunoprecipitate from a whole-cell lysate of NK cells treated with siRNA targeting HS1. The right lane shows the result for cells treated with control siRNA. Middle panel: Immunoblot with anti-Vav1. The left lane shows the presence of Vav1 protein in an anti-HS1 precipitate from a lysate of NK cells treated with control siRNA. The right lane shows the presence of Vav1 in the lysate. Right panel: Similar to the middle panel, except with a lysate from NK cells depleted for HS1.